LT3045474T - Terapiniai agentai, skirti gydyti ligas, susijusias su nepageidaujama ląstelių proliferacija - Google Patents

Terapiniai agentai, skirti gydyti ligas, susijusias su nepageidaujama ląstelių proliferacija

Info

Publication number
LT3045474T
LT3045474T LTEP16155009.0T LT16155009T LT3045474T LT 3045474 T LT3045474 T LT 3045474T LT 16155009 T LT16155009 T LT 16155009T LT 3045474 T LT3045474 T LT 3045474T
Authority
LT
Lithuania
Prior art keywords
treatment
therapeutic agents
cell proliferation
diseases associated
undesired cell
Prior art date
Application number
LTEP16155009.0T
Other languages
English (en)
Inventor
Joan Seoane Suarez
Silvia PEÑUELAS PRIETO
José BASELGA TORRES
Original Assignee
Fundació Privada Institució Catalana De Recerca I Estudis Avancats
Fundació Privada Institut d'Investigació Oncologica de Vall d'Hebron
Fundació Privada Institut De Recerca Hospital Universitari Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Privada Institució Catalana De Recerca I Estudis Avancats, Fundació Privada Institut d'Investigació Oncologica de Vall d'Hebron, Fundació Privada Institut De Recerca Hospital Universitari Vall Hebron filed Critical Fundació Privada Institució Catalana De Recerca I Estudis Avancats
Publication of LT3045474T publication Critical patent/LT3045474T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G01N33/575—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
LTEP16155009.0T 2009-04-03 2010-04-06 Terapiniai agentai, skirti gydyti ligas, susijusias su nepageidaujama ląstelių proliferacija LT3045474T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200900928A ES2363358B1 (es) 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.

Publications (1)

Publication Number Publication Date
LT3045474T true LT3045474T (lt) 2021-05-10

Family

ID=42342718

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16155009.0T LT3045474T (lt) 2009-04-03 2010-04-06 Terapiniai agentai, skirti gydyti ligas, susijusias su nepageidaujama ląstelių proliferacija

Country Status (24)

Country Link
US (4) US10100112B2 (lt)
EP (2) EP2414394A2 (lt)
JP (5) JP6207836B2 (lt)
KR (6) KR20180079470A (lt)
CN (2) CN102574918A (lt)
AU (1) AU2010233791B2 (lt)
BR (1) BRPI1015369A2 (lt)
CA (1) CA2757680C (lt)
CY (1) CY1124148T1 (lt)
DK (1) DK3045474T3 (lt)
EA (1) EA201101450A1 (lt)
ES (2) ES2363358B1 (lt)
HR (1) HRP20210352T1 (lt)
HU (1) HUE054196T2 (lt)
IL (1) IL215467A (lt)
LT (1) LT3045474T (lt)
MX (1) MX336903B (lt)
PL (1) PL3045474T3 (lt)
PT (1) PT3045474T (lt)
SG (2) SG175032A1 (lt)
SI (1) SI3045474T1 (lt)
SM (1) SMT202100153T1 (lt)
WO (1) WO2010115868A2 (lt)
ZA (1) ZA201107215B (lt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3117833B1 (en) * 2005-07-19 2019-01-23 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物
JP2017507969A (ja) * 2014-03-11 2017-03-23 ゴーダーヴァリ バイオリファイナリーズ リミテッド がん幹細胞標的化合物
AU2015284248B2 (en) * 2014-06-30 2020-04-16 Altor Bioscience Corporation IL-15-based molecules and methods of use thereof
CN106687134A (zh) * 2014-09-10 2017-05-17 加利福尼亚大学董事会 通过抗hLIF抗体靶向K‑RAS介导的信号转导通路和恶性肿瘤
EP3067422B1 (en) * 2015-03-13 2024-07-31 Sabanci Üniversitesi Ct-1 inhibitors
WO2016154203A1 (en) 2015-03-23 2016-09-29 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
IL294088B2 (en) * 2016-12-19 2023-10-01 Medimmune Ltd Antibodies against LIF and their uses
KR20210008514A (ko) * 2018-05-14 2021-01-22 메디뮨 리미티드 Lif에 대한 항체 및 이의 투여 형태
EP3807315A2 (en) * 2018-06-18 2021-04-21 MedImmune Limited Methods for improving response to anti-lif antibody treatment in individuals with cancer
EP3806899A2 (en) * 2018-06-18 2021-04-21 MedImmune Limited Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
WO2020056349A2 (en) * 2018-09-13 2020-03-19 Evestra, Inc. Lif/lifr antagonist oncology and nonmalignant diseases
TWI868126B (zh) * 2019-04-17 2025-01-01 國立大學法人廣島大學 以組合投予il-6 抑制劑與ccr2 抑制劑為特徵之泌尿器官癌的治療劑
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
AR243935A1 (es) 1987-12-15 1993-09-30 Gene Shears Pty Ltd Compuesto oligonucleotidico de aplicacion biologica en plantas y excluyendo su uso farmaceutico, metodo para prepararlo y composicion que lo comprende.
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
WO1993023556A1 (en) * 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
GB9413316D0 (en) 1994-07-01 1994-08-24 Cancer Res Campaign Tech Novel proteins
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
ES2313883T3 (es) * 1999-02-12 2009-03-16 The Scripps Research Institute Procedimientos para el tratamiento de tumores y metastasis utilizando una combinacion de terapias antiangiogenicas e inmunoterapias.
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2003218456A1 (en) 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
EP1576131A4 (en) * 2002-08-15 2008-08-13 Genzyme Corp EXPRESSION PATTERN IN BRAIN DENTHELIC CELLS
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040248158A1 (en) * 2003-01-28 2004-12-09 Loughran Thomas P Differentially expressed genes in large granular lymphocyte leukemia
WO2005030803A1 (en) * 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
CN101052717A (zh) * 2004-05-11 2007-10-10 α基因株式会社 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法
BRPI0912927A2 (pt) * 2008-08-29 2019-10-01 Genentech, Inc. "método de detectar um tumor independente de vegf em um indivíduo e método de tratar um tumor independente de vegf em um indivíduo"
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Also Published As

Publication number Publication date
US20240400667A1 (en) 2024-12-05
EP3045474A2 (en) 2016-07-20
US20120114671A1 (en) 2012-05-10
AU2010233791A1 (en) 2011-11-03
KR20220035978A (ko) 2022-03-22
PL3045474T3 (pl) 2021-08-09
EP2414394A2 (en) 2012-02-08
BRPI1015369A2 (pt) 2021-06-29
ES2363358B1 (es) 2012-06-21
KR20180079470A (ko) 2018-07-10
KR102373754B1 (ko) 2022-03-15
HUE054196T2 (hu) 2021-08-30
ES2363358A1 (es) 2011-08-01
JP2022031742A (ja) 2022-02-22
CA2757680A1 (en) 2010-10-14
KR20190093691A (ko) 2019-08-09
JP2012522756A (ja) 2012-09-27
US11999782B2 (en) 2024-06-04
CN107964043A (zh) 2018-04-27
KR20170121319A (ko) 2017-11-01
WO2010115868A3 (en) 2011-02-03
CY1124148T1 (el) 2022-05-27
EP3045474B1 (en) 2021-01-13
JP2019006784A (ja) 2019-01-17
US10100112B2 (en) 2018-10-16
MX336903B (es) 2016-02-04
JP2016040255A (ja) 2016-03-24
EP3045474A3 (en) 2016-09-28
US20200385455A1 (en) 2020-12-10
JP2020090522A (ja) 2020-06-11
CN102574918A (zh) 2012-07-11
AU2010233791B2 (en) 2016-01-21
SG175032A1 (en) 2011-11-28
HRP20210352T1 (hr) 2021-05-28
SI3045474T1 (sl) 2021-07-30
MX2011010425A (es) 2012-03-06
PT3045474T (pt) 2021-03-22
EA201101450A1 (ru) 2012-04-30
CA2757680C (en) 2021-11-02
ES2864639T3 (es) 2021-10-14
KR20120100703A (ko) 2012-09-12
WO2010115868A2 (en) 2010-10-14
IL215467A (en) 2016-06-30
US20190211095A1 (en) 2019-07-11
ZA201107215B (en) 2012-12-27
JP7197665B2 (ja) 2022-12-27
JP6207836B2 (ja) 2017-10-04
SG10202010568RA (en) 2020-11-27
SMT202100153T1 (it) 2021-05-07
IL215467A0 (en) 2011-12-29
KR20200078668A (ko) 2020-07-01
DK3045474T3 (da) 2021-03-22

Similar Documents

Publication Publication Date Title
SG10202010568RA (en) Therapeutic Agents For The Treatment Of Diseases Associated With Undesired Cell Proliferation
IL259475A (en) Combined therapy for the treatment of diabetes
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
ZA200906210B (en) 3-Imidazolyl-Indoles for the treatment of proliferative diseases
IL200368A0 (en) Treatment of diseases characterized by inflammation
PL2643004T3 (pl) Kompozycja oligosacharydów do leczenia chorób skóry
IL215131A0 (en) Methods of treatment using combination therapy
ZA201301601B (en) Treatment of diseases
GB0921075D0 (en) Novel combination of the therapeutic agents
IL218283A0 (en) Combination therapy for treating proliferative diseases
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
PL2280717T3 (pl) Środek terapeutyczny dla chorób beztlenowych
ZA200905364B (en) Treatment of diseases characterized by inflammation
ZA201300762B (en) Novel combination therapy for the treatment of cancer
GB201202095D0 (en) Topical medicament for the treatment of psoriasis
IL275636A (en) Medical combination for cancer treatment
IL216491A0 (en) Combination therapy for the treatment of multiple myeloma
EP2564849A4 (en) PROPHYLACTIC OR THERAPEUTIC FOR DISEASES RELATED TO PAIN IN THE HARNTRAKT
PL2424529T3 (pl) Nowe postępowania terapeutyczne z zastosowaniem centakwiny
GB0901727D0 (en) The treatment of ophthalmic diseases
GB0801511D0 (en) The treatment of ophthalmic diseases
IL222623A (en) Preparations and kits for medical treatment
GB0700755D0 (en) The Treatment of ophthalmic diseases
GB0915802D0 (en) Therapeutic treatments
GB0805119D0 (en) Treatment of myelination diseases